Developing a new class of anti-cancer therapy for patients with advanced disease

Orally bioavailable small molecule with dual mechanisms of action

Granted Orphan Drug Designation for the treatment of glioma

Latest news

New management team in Axelar AB

15 August 2018 The Board of Axelar AB has appointed Vidar Wendel-Hansen as new Chief Executive Officer at the … More »

Clinical Trial Application for Phase I trial of AXL1717 new capsule formulation submitted in India

9 January 2018 Since 2015 Axelar AB has had a co-development agreement with Cadila Pharmaceuticals Ltd for … More »